Not Yet Recruiting
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults - AI447-121
Opdateret:
23 august, 2018
|
ClinicalTrials.gov
Køn
Aldersinterval
Beliggenhed(er)
Not Yet Recruiting
For more information regarding Bristol Myers Squibb (BMS) Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - at least 18 years of age with CHC, GT-1 - treatment-naïve and treatment-experienced (null or partial) responders - intolerant to interferon (IFN) - with or without cirrhosis Exclusion Criteria: - patients who received DCV and ASV as part of a clinical trial - patients who received DCV and ASV for any indication other than that which is locally approved - contraindications included in the approved Mexican prescribing information Other protocol defined inclusion/exclusion criteria could apply
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001